论文部分内容阅读
Purpose:The aim of this study was to evaluate the safety and efficacy of a novel dendritic cell vaccine pulsed with survivin and MUC1, silenced with suppressor of cytokine signaling 1 , and immune stimulated with flagellin for patients with NSCLC in a phase I open-label, uncontrolled, and dose-escalation trial.